摘要:
The invention relates to new 2-pyridine-thiol derivatives of the formula (I), ##STR1## wherein R is hydrogen or alkyl having from 1 to 4 carbon atoms,Z is phenyl optionally substituted by one or more halogen atoms and/or alkyl groups having from 1 to 4 carbon atoms,R.sup.1 and R.sup.2 each independently represents hydrogen, alkyl having from 1 to 4 carbon atoms, alkylphenyl having from 1 to 4 carbon atoms in the alkyl moiety or an ##STR2## group, in which R has the same meaning as defined above, and the substituent ##STR3## is attached to the pyridine ring in the position 3 or 4, with the proviso that if R.sup.1 and R.sup.2 are both methyl and Z is 4-chlorophenyl, R is other than hydrogen, and acid addition salts thereof.The invention further relates to processes for the preparation of the above compounds and to pharmaceutical compositions containing them as active ingredient.The compounds are pharmaceutically active, in particular show cytoprotective activity.
摘要:
New intermediate compounds of the formula (I) are disclosed ##STR1## wherein R is hydrogen or C.sub.1 to C.sub.4 alkyl;Z is phenyl optionally substituted by one or more halogen atoms and/or alkyl groups having 1 to 4 carbon atoms; andD is hydroxy, mesyloxy, p-tosyloxy, or halogen; or pharmaceutically acceptable acid addition salt thereof. The compounds of the Formula (I) are intermediates in the preparation of new compounds having anti-ulcer activity.
摘要:
The invention relates to a new process for the preparation of N-sulfamyl-3-(2-guanidinothiazol-4-yl-methylthio)-propionitrile (famotidine) of the formula (I) ##STR1## by S-alkylation of 2-guanidino-thiazol-4-yl-methanethiol obtained from S-(2-guanidino-thiazol-4-yl-methyl)-isothiourea dihydrochloride of the formula (III) ##STR2## by in situ treatment with a base, which comprises carrying out S-alkylation with a N-sulfamyl-3-halopropionamidine of the formula (II) ##STR3## wherein X stands for halogen.
摘要:
The object of the present invention are new desloratadine salts of formula I wherein the meaning of X is an acid residue and the meaning of n is 1 or 2, and formula II wherein the meaning of X is a pK
摘要:
The invention relates to a new process for the synthesis of 17&bgr;-hydroxy-17&agr;-methyl-1,3-seco-2-nor-5&agr;-androstane-3-acid derivatives of formula (I) wherein the meaning of Z is carboxyl or formyl group and to the new secoindoxylidene carboxylic acid derivatives of formula (II) wherein R1 and R2 independently are C1-C4 alkyl or alkoxy group, hydrogen or halogen atom—which are intermediates for preparing the compounds of formula (I). The 17&bgr;-hydroxy-17&agr;-methyl-1,3-seco-2-nor-5&agr;-androstane-3-acid derivatives of formula (I) are intermediates in the synthesis of oxandrolon (17&bgr;-hydroxy-17&agr;-methyl-2-oxa-5&agr;-androstane-3-one), which is used as anabolic in therapy.
摘要:
The invention relates to the novel 2,6-bis(chloromethyloxy-carbonyloxymethyl)pyridine of the formula (I) ##STR1## as well as a process for the preparation of this compound, which is a useful intermediate in the preparation of the anti-atherosclerotic 2,6-bis(hydroxymethyl)pyridine bis(N-methylcarbamate) (pyridinolcarbamate) and other drugs.According to the invention, the compound of the formula (I) is prepared by reacting 2,6-bis(hydroxymethyl)pyridine of the formula (II) ##STR2## with chloromethyl chloroformate of the formula (III) ##STR3## in a polar-aprotic, water-immiscible organic solvent, in the presence of a basic substance between about -30.degree. C. and +10.degree. C.
摘要:
A new process is disclosed for the synthesis of racemic or optically pure N-[4-cyano-3-trifluoro-methyl-phenyl]-3[4-fluorophenyl-sulfonyl]-2-hydroxy-2-methylpropionamide. The process includes the formation of several novel intermediates in the synthesis.
摘要:
The antifungal agent (E)-N-methyl-N-(1-naphthylmethyl)-6,6-dimethyl-hept-2-ene-4-ynyl-1-amine of formula (I) and acid addition salts thereof are prepared by reacting a chloro-compound of formula (IIIb) with a secondary amine of formula (II) in an aliphatic ketone-type solvent in the presence of a base and optionally iodide salt catalyst, and subsequently treating the resulting reaction mixture directly with aqueous hydrochloric acid to precipitate the hydrochloride of the compound of formula (I). The precipitate is separated, and the base of formula (I) can be liberated from the hydrochloride and can be converted into other pharmaceutically acceptable acid addition salts.
摘要:
The invention relates to carbazolone derivatives of the formula ##STR1## wherein A stands for a group of formula--CH.sub.2 --R (V), wherein R means a hydroxyl or 2-methyl-1H-imidazol-1-yl group;B represents a group of formula ##STR2## wherein R.sub.1 means hydrogen or a methyl or ethyl group; or A and B together form a group of formula ##STR3## wherein R.sub.2 means a methyl or ethyl group; or A and B together form a group of formula ##STR4## The above compounds are useful intermediates in the synthesis of ondansetron of formula ##STR5## chemically 9-methyl-3-[(2-methyl-1H-imidazol-1-yl)methyl]-1,2,3,9-tetrahydro-4H-carbazol-4-one.The invention further relates to a novel process for the preparation of compounds of the formula (I) , wherein A and B are the same as in formula (I) but B may be also hydrogen. Thus, this novel process is suitable for the preparation of ondansetron itself.
摘要:
The invention relates to carbazolone derivatives of the formula ##STR1## wherein A stands for a group of formula--CH.sub.2 --R (V), wherein R means a hydroxyl or 2-methyl-1H-imidazol-1-yl group;B represents a group of formula ##STR2## wherein R.sub.1 means hydrogen or a methyl or ethyl group; or A and B together form a group of formula ##STR3## wherein R.sub.2 means a methyl or ethyl group; or A and B together form a group of formula ##STR4## The above compounds are useful intermediates in the synthesis of ondansetron of formula ##STR5## chemically 9-methyl-3-[(2-methyl)-1H-imidzol-1-yl)methyl]1,2,3,9-tetrahydro-4H-carbazol-4-one.The invention further relates to a novel process for the preparation of compounds of the formula (I), wherein A and B are the same as in formula (I) but B may be also hydrogen. Thus, this novel process is suitable for the preparation of ondansetron itself.